About the Company
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MORF News
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of ...
Commit To Buy Morphic Holding At $20, Earn 10.9% Annualized Using Options
Investors considering a purchase of Morphic Holding Inc (Symbol: MORF) shares, but tentative about paying the going market price of $34.97/share, might benefit from considering selling puts among ...
Morphic Appoints Simon Cooper As Chief Medical Officer
Morphic Holding, Inc. (MORF) on Tuesday announced the appointment of Simon Cooper as the Chief Medical Officer. With a background in ...
Morphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy Rating
Morphic Holding (MORF) Company Description: Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics.
Morphic Holding Inc MORF
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
Morphic Holding, Inc. (MORF) closed the last trading session at $35.30, gaining 16.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...
New Strong Buy Stocks for February 14th
Lumen Technologies, Inc. price-consensus-chart | Lumen Technologies, Inc. Quote Morphic Holding, Inc. MORF: This ...
Morphic Holding (MORF) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Morphic Holding Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...